Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next? - Osteoporosis International Aromatase inhibitors (AIs) are one of the adjuvant endocrine therapies of choice, for estrogen receptor-positive breast cancer in postmenopausal women and premenopausal women with ovarian suppression....

📢 New review by an IOF Working Group:
For women with non-metastatic breast #cancer receiving aromatase inhibitors, #denosumab reduces bone loss & fracture risk—but stopping denosumab raises clinical challenges. Read our new review provides for important insights & strategies.

Read 🔗 bit.ly/4rhwGFo

Mabwell's Strategic Global Expansion with First Overseas Shipment of Denosumab Injection Mabwell has made a significant move by announcing the first overseas shipment of its Denosumab Injection, emphasizing its globalization strategy and market expansion.

Mabwell's Strategic Global Expansion with First Overseas Shipment of Denosumab Injection #China #Shanghai #pharmaceuticals #Denosumab #Mabwell

Accord Healthcare Launches Denosumab Biosimilars for Bone Health Accord Healthcare introduces Osvyrti and Jubereq, two biosimilars of Denosumab, aimed at improving bone health access for patients.

Accord Healthcare Launches Denosumab Biosimilars for Bone Health #None #Denosumab #OSVYRTI #Jubereq

Accord BioPharma Receives FDA Approval for New Denosumab Biosimilars Accord BioPharma has announced the FDA approval of two denosumab biosimilars, OSVYRTI and JUBEREQ, expanding its offerings in treatments for osteoporosis and cancer-related conditions.

Accord BioPharma Receives FDA Approval for New Denosumab Biosimilars #United_States #Accord_BioPharma #Raleigh,_N.C. #Denosumab #OSVYRTI

GlycoNex Completes Patient Dosing for Phase 3 Trial of SPD8 Biosimilar for Osteoporosis GlycoNex has successfully completed the final patient dosing in its Phase 3 trial of SPD8, a denosumab biosimilar aimed at treating osteoporosis, with top-line results expected in 2026.

GlycoNex Completes Patient Dosing for Phase 3 Trial of SPD8 Biosimilar for Osteoporosis #Taiwan #New_Taipei_City #GlycoNex #SPD8 #Denosumab

Epileptic seizures associated with denosumab Denosumab is known to be associated with adverse reactions such as hypocalcemia but this is the first reported case of epileptic seizures, underscoring the need for vigilance regarding such rare side…

#MedCase - #Denosumab is known to be associated with adverse reactions such as hypocalcemia but this is the first reported case of epileptic seizures, underscoring the need for vigilance regarding such rare side effects.

👉 buff.ly/0CyjgWV

#Osteoporosis #RheumSky

Mabwell Achieves Landmark Approval for Denosumab Injection in Pakistan Mabwell, in collaboration with The Searle Company, has gained Pakistan's first approval for denosumab injections, enhancing local treatment options.

Mabwell Achieves Landmark Approval for Denosumab Injection in Pakistan #Pakistan #Karachi #Denosumab #Mabwell #Searle

Research Article

Long-Term Effectiveness and Safety of Denosumab for Osteoporosis in Patients With Rheumatic Diseases

📖 www.jrheum.org/cgi/content/...

#denosumab #glucocorticoids #osteoporosis

Editorial

Denosumab for Osteoporosis Treatment in Rheumatic Diseases: What Do We Know 15 Years Post Approval?

📖 doi.org/10.3899/jrhe...

#denosumab #osteoporosis

Stada revives talk of an IPO – if conditions improve Germany's Stada has said it may make another attempt to seek a public listing in the autumn, after delaying its plans earlier this year.

#Stada #IPO #pharmaindustry #generics #OTC #specialtymedicines #rarediseases #chronicdiseases #biosimilars #plaquepsoriasis #psoriaticarthritis #Crohnsdisease #specialtybiosimilars #aflibercept #denosumab #golimumab #tocilizumab #blockbusterdrugs #GLP1agonists #diabetes #obesity
zurl.co/nbsw4

En dan stean je dus je tosken te poetsen wêrfan je witte dat wat der noch yn de boppekaak sit, der mei in goed oere úthelle wurdt🤔😁
#osteoporose #denosumab

European Commission Grants Approval for Biocon Biologics' New Denosumab Biosimilars to Enhance Bone Health The European Commission has authorized Biocon Biologics' Denosumab biosimilars, Vevzuo and Evfraxy, for improved bone health in cancer and osteoporosis patients.

European Commission Grants Approval for Biocon Biologics' New Denosumab Biosimilars to Enhance Bone Health #None #Denosumab #Biocon_Biologics #Vevzuo

European Commission Approves Biocon Biologics' Denosumab Biosimilars for Bone Health Biocon Biologics has received European Commission approval for its Denosumab biosimilars, Vevzuo® and Evfraxy®, enhancing bone health treatments in Europe.

European Commission Approves Biocon Biologics' Denosumab Biosimilars for Bone Health #India #Bangalore #Denosumab #Biocon_Biologics #Osteoporosis

European Commission Approves Biocon's Denosumab Biosimilars for Bone Health Biocon Biologics announces successful approval of Denosumab biosimilars Vevzuo and Evfraxy by the European Commission to enhance bone health treatment access.

European Commission Approves Biocon's Denosumab Biosimilars for Bone Health #India #Bengaluru #Denosumab #Biosimilars #Biocon_Biologics

European Commission Grants Approval for Biocon Biologics’ Denosumab Biosimilars, Vevzuo and Evfraxy Biocon Biologics Ltd has received European Commission approval for its biosimilars, Vevzuo® and Evfraxy®, aimed at improving bone health and treating osteoporosis.

European Commission Grants Approval for Biocon Biologics’ Denosumab Biosimilars, Vevzuo and Evfraxy #India #Bengaluru #Denosumab #Biocon_Biologics #Vevzuo

mAbxience Achieves Milestone with European Approval for Denosumab Biosimilars mAbxience proudly announces the European Commission's approval of its denosumab biosimilars, Denbrayce® and Izamby®, enhancing access to critical therapies.

mAbxience Achieves Milestone with European Approval for Denosumab Biosimilars #Spain #Madrid #Fresenius_Kabi #Denosumab #mAbxience

mAbxience Celebrates European Commission Approval for Denosumab Biosimilars mAbxience announces that the European Commission has approved its Denosumab biosimilars, promising improved access to critical therapies across Europe.

mAbxience Celebrates European Commission Approval for Denosumab Biosimilars #Spain #Madrid #Fresenius_Kabi #Denosumab #mAbxience

Yn oktober/novimber 4 x nei in foar my nije toskedokter west, dat gie net goed.
Sûnt jannewaris oare praktyk:
6 x toskedokter
2 x kaaksjirurch
1 x mûlhygiëniste (oars ek west)
1 x tosktechnikus
Noch mear te gean. Ik hoopje yn augustus klear te wêzen😁
#osteoporose #denosumab

#Denosumab offers a convenient alternative to bisphosphonates for #osteoporosis treatment but carries risks such as rebound fractures upon discontinuation.

ja.ma/43djRTo

Biocon Biologics Gains Favorable CHMP Opinions for Denosumab Biosimilars in Europe Biocon Biologics has received positive recommendations from CHMP for its denosumab biosimilars aimed at bone health, paving the way for new treatment options.

Biocon Biologics Gains Favorable CHMP Opinions for Denosumab Biosimilars in Europe #India #Bengaluru #Denosumab #Biocon_Biologics #Vevzuo

Biocon Biologics Secures Positive CHMP Opinions for Denosumab Biosimilar in Europe Biocon Biologics Ltd has received encouraging recommendations from the CHMP for its Denosumab biosimilar aimed at improving bone health in Europe.

Biocon Biologics Secures Positive CHMP Opinions for Denosumab Biosimilar in Europe #India #Bengaluru #Denosumab #Biocon_Biologics #Vevzuo

Positive CHMP Opinions Boost Biocon Biologics’ Biosimilar Denosumab for Bone Health in Europe Biocon Biologics has received favorable reviews from the CHMP for its Denosumab biosimilars targeting bone health, marking a significant milestone.

Positive CHMP Opinions Boost Biocon Biologics’ Biosimilar Denosumab for Bone Health in Europe #India #Bengaluru #Denosumab #Biosimilars #Biocon_Biologics

Biocon Biologics Achieves Positive CHMP Recommendations for Denosumab Biosimilars in Europe Biocon Biologics has received positive opinions from the CHMP in Europe for its biosimilars of Denosumab, affirming their efficacy and safety for bone health.

Biocon Biologics Achieves Positive CHMP Recommendations for Denosumab Biosimilars in Europe #India #Bengaluru #Biocon #Denosumab #Biosimilars

Real-world differences in denosumab persistence, reinitiation, and switching among cohorts of older adults in Canada and the United States Abstract. Denosumab is an injectable osteoporosis medication administered twice per year. Discontinuation of denosumab can result in rapid rebound fracture

Real-world persistence with #denosumab, an urgent matter requiring system improvements
academic.oup.com/jbmrplus/adv...

🦀🦴Treatment of Cancer-Associated Hypercalcemia

➡️Start with IV fluids
➡️Then hit osteoclasts with #Bisphosphonates or #Denosumab

But remember, real control = treating the malignancy

🔗 www.nejm.org/doi/full/10....

#Hypercalcemia #Malignancy #OncoNephrology #Nephrology #IM #Oncology #MedSky #NephSky

New biosimilar approved

#Medsky🧪#pharmasky
@fda.gov approves second biosimilars to #Prolia & #Xgeva ( #denosumab) Denosumab is a type of targeted Drug #monoclonalantibody. It is for secondary bone cancer Tx . bnf.nice.org.uk/drugs/denosu...

www.accessdata.fda.gov/drugsatfda_d...

Cardiovascular Safety and Fracture Prevention Effectiveness of Denosumab Versus Oral Bisphosphonates in Patients Receiving Dialysis: A Target Trial Emulation: Annals of Internal Medicine: Vol 0, No 0 Background: Dialysis patients have high rates of fracture morbidity, but evidence on optimal management strategies for osteoporosis is scarce. Objective: To determine the risk for cardiovascular event...

Bombshell from @annalsofim.bsky.social

#Denosumab or Prolia compared to Oral bisphosphonates in dialysis

Target Trial Emulation, from Japan

45% Less fractures
36% higher MACE!

www.acpjournals.org/doi/10.7326/... 🔒

GlycoNex Begins Phase 3 Trial of SPD8 Biosimilar for Osteoporosis Treatment GlycoNex has announced the first patient dosed in a Phase 3 trial for its biosimilar, SPD8, aimed at treating osteoporosis. Results expected in 2026.

GlycoNex Begins Phase 3 Trial of SPD8 Biosimilar for Osteoporosis Treatment #Taiwan #New_Taipei_City #GlycoNex #SPD8 #Denosumab